Coloplast A/S (CLPBY) Stock

About Coloplast A/S

Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services. Its extensive reach spans Denmark, the United States, the United Kingdom, France, and numerous other international regions. The company's activities are organized into three primary segments: Chronic Care, Interventional Urology, and Wound & Skin Care. Within Chronic Care, Coloplast provides advanced ostomy solutions, including the SenSura Mio, recognized for its adaptable fit and discretion, alongside other SenSura offerings and Brava brand accessories. This segment also delivers continence care products such as Conveen Active urine bags, SpeediCath catheters for diverse users, and the Peristeen transanal irrigation system. The Wound & Skin Care division features innovative dressings like the conforming Biatain Silicone and the hydrocolloid Comfeel. Additionally, it offers a broad spectrum of skin care items, encompassing bathing and cleansing products, moisturizers, skin protectants, antifungal treatments, hand cleansers, odor control solutions, and the specialized InterDry system for managing skin folds. Finally, the Interventional Urology segment is dedicated to crafting and commercializing surgical devices that address a range of urological and gynecological conditions, such as urinary stone disease, benign prostatic hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence.

Coloplast A/S is headquartered in DK.

Coloplast A/S (CLPBY) stock trades at $6.31 with a market capitalization of $14.21B. The stock is valued at a price-to-earnings (P/E) ratio of 44.03, price-to-book of 7.22, price-to-sales of 3.30. Over the past 52 weeks the stock has ranged between $5.64 and $10.03, and currently trades 37.1% below its 52-week high. It pays a dividend yielding 2.54%.

On profitability, Coloplast A/S generates a return on equity (ROE) of 14.23%, above the typical market average, return on capital employed of 18.25%, an operating margin of 26.47%, a net profit margin of 7.51%.

Official website: www.coloplast.com